BCL2 and neuroblastoma: In line with previous results obtained with ABT263, neuroblastoma cell lines expressing high BCL-2 mRNA levels responded more potently to ABT199 than low BCL-2-expressing cell lines, with an over 90-fold difference in average LC50 value (i.e., 0.17 μM versus 15.46 μM, respectively).